Abstract:Well-characterized, high-quality fresh-frozen prostate tissue is required for prostate cancer research. As part of the PROCURE Prostate Cancer Biobank launched in 2007, four University Hospitals in Quebec joined to bank fresh frozen prostate tissues from radical prostatectomies (RP). As the biobank progressed towards allocation, the nature and quality of the tissues were determined. RP tissues were collected by standardized alternate mirror-image or biopsy-based targeted methods, and frozen for banking. Clinical/pathological parameters were captured. For quality control, two presumed benign and two presumed cancerous frozen, biobanked tissue blocks per case (10/site) were randomly selected during the five years of collection. In a consensus meeting, 4 pathologists blindly evaluated slides (n=160) and graded quality, Gleason score (GS), and size of cancer foci. The quality of tissue RNA (37/40 cases) was assessed using the RNA Integrity Number. The biobank included 1819 patients of mean age: 62.1 years; serum PSA: 8 ng/ml; prostate weight: 47.8 g; GS: 7; and pathological stage: T2 in 64.5%, T3A in 25.5% and T3B in 10% of cases. Of the 157 evaluable slides, 79 and 78 had benign and cancer tissue, respectively. GS for the 37 cancer-positive cases were: 6 in 9, 7 in 18 and >7 in 10 and, in most instances, in concordance with final GS. In 40% of slides containing cancer, foci occupied ≥50% of block surface and 42% had a diameter ≥1 cm. Tissue was well preserved and consistently yielded RNA of very good quality with RNA Integrity Number (RIN) >7 for 97% of cases (mean=8.7 ± 0.7) during the five-year collection period. This study confirms the high quality of randomly selected benign and cancerous fresh-frozen prostate tissues of the PROCURE Quebec Prostate Cancer Biobank. These results strengthen the uniqueness of this large prospective resource for prostate cancer research.

Establishment of MR imaging biobank of prostate

A New Technique in Fresh Prostate Cancer Tissue Biobanking Based on MRI-Transrectal Ultrasound Fusion Biopsy.

Real-time precision targeted prostate biopsy using transrectal ultrasound-magnetic resonance fusion

Establishment and Management of a Lung Cancer Biobank in Eastern China.

Establishment of A Network-Based Intra-Hospital Virtual Cancer Biobank

Retrospect of 15-year construction and progress of biobank for gastrointestinal cancer in China

MRI/US imaging fusion guided transperineal prostate biopsy:a research in single center

Establishment, maintenance and management of liver tumor biobank

Integrating Clinical and Biological Information in a Shanghai Biobank: an Introduction to the Sample Repository and Information Sharing Platform Project.

[The Breast Cancer Cohort Study in Chinese Women: the construction and progress of the pan-shared biobank]

Supplementary Data [S-1] from Prebiopsy Mp-Mri Can Help to Improve the Predictive Performance in Prostate Cancer: A Prospective Study in 1,478 Consecutive Patients

Artificial Intelligence for Screening Chinese Electronic Medical Record and Biobank Information

[Biobank in the Age of Big Data].

The establishment and administration of obstetric and gynecologic biobank

Feasibility and safety study of advanced prostate biopsy robot system based on MR-TRUS Image flexible fusion technology in animal experiments

Establishment of the Medical Imaging Database of Breast and Its Clinical Significance

Strategies for biochemical and pathologic quality assurance in a large multi-institutional biorepository; The experience of the PROCURE Quebec Prostate Cancer Biobank

A Fundamental Role of Biobank in Biomedical Research

Avoiding Unnecessary Systematic Biopsy in Clinically Significant Prostate Cancer: Comparison Between MRI‐Based Radiomics Model and PI‐RADS Category

Utilization trend of prebiopsy multiparametric magnetic resonance imaging and its impact on prostate cancer detection: Real‐world insights from a high‐volume center in southwest China

Combined MRI-TRUS fusion targeted and systematic biopsy versus systematic biopsy alone for the detection of prostate cancer: protocol for a prospective single-centre trial